ONMD

MINNEAPOLIS, Sept. 25, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “Company,” “we,” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced that it will implement a 1-for-10 reverse stock split of its issued and outstanding shares of common stock (the “Reverse Stock Split”), effective at 12:01 a.m.

MINNEAPOLIS, Sept. 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us,” or “our”), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), today announced a strategic partnership with Atropos Health, the creator of real-world evidence for clinical decision-making under a multi-year agreement.

MINNEAPOLIS, Sept. 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced year-to-date bookings of approximately $16.2 million, a 16X increase versus the same period in 2025.

MINNEAPOLIS, Aug. 31, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced a new agreement to deliver de-identified, full-fidelity clinical Real-World Data to a leading AI-driven drug development company. OneMedNet's iRWD™ Platform enabled cohort feasibility within minutes, data validation within a week, and signed contract within three weeks of initial contact, and is now delivering the data to support the customer's development and validation of AI models designed to accelerate and improve how new therapies are discovered and developed.

MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), today announced it has entered into an agreement to supply its regulatory-grade, multi-modal imaging-centric iRWD™ platform data for use in the development and training of a foundational AI model. Under the terms of the agreement, OneMedNet will provide high-quality, de-identified, regulatory-grade healthcare data, including millions of medical imaging and associated clinical reports, with data delivery immediately.

MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), today announced that its OneMedNet iRWD™ Network, has surpassed 90 million patient journeys and 270 million studies, with a healthcare partner network now exceeding 2,300 sites. The milestone represents direct progress against the strategic priorities the Company laid out to shareholders at the close of 2025, when OneMedNet identified expansion of its data network as a core pillar of long-term value creation.

MINNEAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), today announced that its OneMedNet iRWD™ Platform, built on Palantir Foundry, is now live and fully operational. This major commercialization milestone delivers searchable access to billions of records across 80 million patient journeys in seconds, transforming how life sciences organizations access and analyze multi-modal clinical data at unprecedented scale and speed.